DUBLIN – Sangamo Therapeutics Inc. is picking up Txcell SA, a French developer of chimeric antigen receptor T-regulatory cell (CAR-Treg) therapy in a cash deal valued at €72 million (US$84.4 million), which includes about €6 million of debt on Txcell's balance sheet. The transaction, which is expected to close in the fourth quarter, values Valbonne-based Txcell at €2.58 per share.